{"a":[{"_":"Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen","$":{"href":"/biotech/novartis-inks-32b-subcutaneous-drug-delivery-deal-alteogen","hreflang":"en"}}]}

Summary

Novartis has entered into a partnership worth up to $3.2 billion with Alteogen to access subcutaneous drug delivery technology, joining other major pharmaceutical companies such as Biogen and GSK in licensing the platform.